As a pharmacotherapeutic specialist in infectious diseases, my research interests lie within public health communicable disease control. My research and training environment focuses on policy-related work with respect to evaluating the clinical impact of antimicrobial agents in studies of specific patient subgroups and in population-based cohorts as well as cost-effectiveness of various public health programs. Population-based use of antimicrobial agents and impact on diseases I am interested in surveillance of anti-infective agents at a population level as well as use of these agents in patients with tuberculosis, sexually transmitted diseases and other communicable diseases. Health outcomes associated with interventions associated with communicable diseases I am interested in evaluating health outcomes associated with various immunization and TB control programs such as cost-effectiveness of vaccination programs for the province of British Columbia, resources and health care utilization due to communicable diseases.
Relevant NGDI Articles
A meta-analysis of intradermal versus intramuscular influenza vaccines: immunogenicity and adverse events. Marra F, Young F, Richardson K, Marra CA. Influenza Other Respir Viruses. 2013 Jul;7(4):584-603. Review.
A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework. Sadatsafavi M, Marra C, Marra F, Moran O, FitzGerald JM, Lynd L. Value Health. 2013 Jan-Feb;16(1):66-75.
Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada. Marra F, Chong M, Henry B, Patrick DM, Kendall P. J Antimicrob Chemother. 2013 Dec 16.
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, Langley JM, Bettinger JA, Singer J, Money D, Miller D, Naus M, Marra F, Young E. JAMA. 2013 May 1;309(17):1793-802.
Antimicrobial use for skin and soft tissue infections in Canada in an era of CA-MRSA. Marra F, Chong M, McKay R and Patrick D. Clin Microbiol Infect 2012 18:66.
Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use. Marra F, Patrick DM, Chong M, McKay R, Hoang L and Bowie WR. Antimicrob Agents Chemother 2012 56(12):6243-6249.
The cost effectiveness of human papillomavirus vaccines: A systematic review. Seto K, Marra F, Raymakers A and Marra CA. Drugs 2012 72(5):715-743.